부산대학교 도서관

We evaluate the impact of ledipasvir on both tenofovir plasma trough concentration and estimated glomerular renal function in human immunodeficiency virus–hepatitis C virus coinfected patients receiving a tenofovir‐based antiretroviral regimen and treated with ledipasvir/sofosbuvir. Twenty‐six patients [81% male, median age: 51 years; hepatitis C virus genotype 1(75%)/4(15%)] were included. Tenofovir trough concentration (interquartile range) increased from 78 ng ml–1 (53–110) at baseline to 141 ng ml–1 (72–176) at 1 month (P = 0.003). No significant difference on estimated glomerular renal function using both Cockroft–Gault and Modification of Diet in Renal Disease formulae, respectively, [median (interquartile range)] was observed between baseline [101.3 ml min–1 (91.1–114.1); 95.6 ml min–1 (86.5–111.2)], 1 month [102.4 ml min–1 (89.8–112.9), P = 0.26; 92.5 ml min–1 (88.1–114.3), P = 0.27], end‐of‐treatment [96.5 ml min–1 (82.4–115.4), P = 0.39; 95.4 ml min–1 (84.2–105.4), P = 0.16] and 12 weeks after the end of treatment [100.5 ml min–1 (83.3–111.9), P = 0.24; 93.4 ml min–1 (82.2–103.5), P = 0.16]. Three patients progressed from chronic kidney disease stage 1 to stage 2 at 12 weeks post‐treatment. A significant increase in tenofovir exposure through P‐glycoprotein inhibition by ledipasvir was confirmed without significant impact on glomerular renal function in our population with normal renal function or mild renal impairment. [ABSTRACT FROM AUTHOR]